Rina Sor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rina Sor has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Robert H. Vonderheide
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
50 shared publications - Ben Z. Stanger
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
49 shared publications - Cynthia Clendenin
University of Pennsylvania Perelman School of Medicine, Abramson Cancer Center, Philadelphia, USA
49 shared publications - William P. Vostrejs
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
48 shared publications - Il-Kyu Kim
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
46 shared publications - Nune Markosyan
Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
46 shared publications
Latest Publications
- Top Cited Papers
- 12 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6790) , 1161-1166
Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma
Transformation of pancreatic epithelial cells to malignant pancreatic ductal adenocarcinoma (PDAC) typically involves the progression of precancerous pancreatic intraepithelial neoplasia (PanINs) bearing oncogenic KRAS mutations. Here, we tested the impact of PDAC interception using either RAS(ON) multiselective or RAS(ON) G12D-selective pharmacological inhibitors [RAS(ON) inhibitors] in mouse models of PDAC. Treatment of PanIN-bearing mice with RAS(ON) inhibitors prompted regression of premalignant lesions that translated into a delay in tumor onset and an increase in overall survival (OS). Long-term interception in tumor-prone mice resulted in a median OS of more than 1 year compared with less than 5 months in nonintercepted control mice ( P < 0.0001). Comparing the survival benefits of RAS(ON) inhibition for cancer interception versus RAS(ON) inhibition for cancer treatment, we found that interception provided a greater survival benefit to mice. These findings suggest that a pharmacological approach may reduce premalignant burden and increase survival in PDAC.
- 12 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6790) , 1161-1166
Top Cited PapersCancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma
Transformation of pancreatic epithelial cells to malignant pancreatic ductal adenocarcinoma (PDAC) typically involves the progression of precancerous pancreatic intraepithelial neoplasia (PanINs) bearing oncogenic KRAS mutations. Here, we tested the impact of PDAC interception using either RAS(ON) multiselective or RAS(ON) G12D-selective pharmacological inhibitors [RAS(ON) inhibitors] in mouse models of PDAC. Treatment of PanIN-bearing mice with RAS(ON) inhibitors prompted regression of premalignant lesions that translated into a delay in tumor onset and an increase in overall survival (OS). Long-term interception in tumor-prone mice resulted in a median OS of more than 1 year compared with less than 5 months in nonintercepted control mice ( P < 0.0001). Comparing the survival benefits of RAS(ON) inhibition for cancer interception versus RAS(ON) inhibition for cancer treatment, we found that interception provided a greater survival benefit to mice. These findings suggest that a pharmacological approach may reduce premalignant burden and increase survival in PDAC.
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 selectively inhibits KRASG12D and downstream MAPK signaling in vitro
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 selectively inhibits KRASG12D and downstream MAPK signaling in vitro
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 is selective for KRASG12D in immunocompetent implantation tumor models
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 is selective for KRASG12D in immunocompetent implantation tumor models
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 reduces metastatic burden in a tail vein model
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 reduces metastatic burden in a tail vein model
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Supplementary Figures and Table with legend arranged in a single presentable package
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Supplementary Figures and Table with legend arranged in a single presentable package
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 exerts in vivo effects early in treatment
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 exerts in vivo effects early in treatment
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
KRASG12D inhibition alters the tumor immune microenvironment
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
KRASG12D inhibition alters the tumor immune microenvironment
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 elicits changes in the tumor stroma and vasculature
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 elicits changes in the tumor stroma and vasculature
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Effects of MRTX1133 in KPC/Y and subcutaneous models
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Effects of MRTX1133 in KPC/Y and subcutaneous models